Article
Automated Quantitative CD8+ Tumor-Infiltrating Lymphocytes and Tumor Mutation Burden as Independent Biomarkers in Melanoma Patients Receiving Front-Line Anti-PD-1 Immunotherapy.
The oncologist - 5 Jul 2024
Fortman Dylan, Karunamurthy Arivarasan, Hartman Douglas, Wang Hong, Seigh Lindsey, Abukhiran Ibrahim, Najjar Yana G, Pantanowitz Liron, Zarour Hassane M, Kirkwood John M, Davar Diwakar
Abstract excerpt
BACKGROUND: CD8+ tumor-infiltrating lymphocyte (TIL) predicts response to anti-PD-(L)1 therapy. However, there remains no standardized method to assess CD8+ TIL in melanoma, and developing a specific, cost-effective, reproducible, and clinically actionable biomarker to anti-PD-(L)1 remains elusive. We report on the development of automatic CD8+ TIL density quantification via whole slide image (WSI) analysis in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.